To observe the clinical efficacy and the change of airway responsiveness to Chinese medicine （CM） in treating cough variant asthma （CVA）. Methods： Ninety-four patients who had confirmed the diagnosis of CVA were ...To observe the clinical efficacy and the change of airway responsiveness to Chinese medicine （CM） in treating cough variant asthma （CVA）. Methods： Ninety-four patients who had confirmed the diagnosis of CVA were selected and randomly assigned to the treatment group and the control group by the blocked randomization method. The ratio of the two groups was 2：1. The treatment group had 63 patients that were treated by CM, lost in 10 cases, 53 patients had finished the trial. The control group had 31 patients that were treated by montelukast tablets and theophylline, lost in 5 cases, 26 patients had finished the trial, two weeks as one therapeutic course. The syndrome efficacy, cough efficacy, symptom score and the airway responsiveness between two groups were observed. Results： The comparison of the syndrome efficacy： the total effective rate of the treatment group was 90.57% and the control group was 76.92%, and the two groups were significantly different （P〈0.05）. The comparison of the cough efficacy： the total effective rate of the treatment group was 98.11% and the control group was 80.77%, and the two groups were also significantly different （P〈0.05）. Syndrome scoring and cough scoring were all significantly lowered, but the airway responsiveness was not significantly lowered. Conclusions： The treatment of CM could ease the cough, improve the syndrome, and shows obvious advantages compared with the control group, which is worthy of extensive clinical application.展开更多
基金Supported by the Third Advantage Project of Xiyuan Hospital of China Academy of Chinese Medical Sciences(No. CACMS08Y0033)
文摘To observe the clinical efficacy and the change of airway responsiveness to Chinese medicine （CM） in treating cough variant asthma （CVA）. Methods： Ninety-four patients who had confirmed the diagnosis of CVA were selected and randomly assigned to the treatment group and the control group by the blocked randomization method. The ratio of the two groups was 2：1. The treatment group had 63 patients that were treated by CM, lost in 10 cases, 53 patients had finished the trial. The control group had 31 patients that were treated by montelukast tablets and theophylline, lost in 5 cases, 26 patients had finished the trial, two weeks as one therapeutic course. The syndrome efficacy, cough efficacy, symptom score and the airway responsiveness between two groups were observed. Results： The comparison of the syndrome efficacy： the total effective rate of the treatment group was 90.57% and the control group was 76.92%, and the two groups were significantly different （P〈0.05）. The comparison of the cough efficacy： the total effective rate of the treatment group was 98.11% and the control group was 80.77%, and the two groups were also significantly different （P〈0.05）. Syndrome scoring and cough scoring were all significantly lowered, but the airway responsiveness was not significantly lowered. Conclusions： The treatment of CM could ease the cough, improve the syndrome, and shows obvious advantages compared with the control group, which is worthy of extensive clinical application.
